Company Insights

ICU customer relationships

Explore interactive graphBrowse insights index
ICU customer relationship map

SeaStar Medical (ICU) — Institutional Customer Map and Commercial Implications

SeaStar Medical commercializes QUELIMMUNE, a pediatric Selective Cytopheretic Device (SCD) sold into hospitals and integrated into continuous renal replacement therapy (CRRT) circuits; the company generates revenue by selling SCD cartridges to hospital operators and, historically, through distribution agreements, while advancing an adult SCD through pivotal trials aimed at broader market monetization. Investors should value SeaStar as a nascent commercial-stage medical device company with concentrated early revenues, clinical-institutional adoption as the primary growth vector, and regulatory/reimbursement outcomes that will determine scale. For an actionable customer-relationship view, see the NullExposure homepage: https://nullexposure.com/

What the commercial roll‑out looks like today

SeaStar received FDA HDE approval for its pediatric SCD (QUELIMMUNE) on February 21, 2024, shipped first commercial units in July 2024, and has recognized modest revenue (~$0.1M in 2024) while building direct commercial capability after ending an upstream distributor relationship. The company is in an early ramp: a small number of high-profile pediatric hospitals have adopted therapy and are contributing registry and survival data that drive medical adoption and reimbursement conversations. Learn more on NullExposure: https://nullexposure.com/

Customer roster: which hospitals are using or reporting on SCD therapy

Below are every institutional relationships referenced in public coverage of SeaStar’s FY2026 commercial activity. Each entry is a one- or two-sentence plain-English summary with the cited source.

Cincinnati Children’s Hospital

Cincinnati Children’s is named among major pediatric institutions that have adopted SCD therapy and reported findings as SeaStar transitioned into commercial sales in FY2026. According to SeaStar’s FY2026 milestone release distributed via GlobeNewswire (published in The Manila Times, Jan 2026), Cincinnati Children’s is an adopter.

Stanford Medical Center

Stanford Medical Center is listed as a major pediatric adopter of SCD therapy in SeaStar’s FY2026 milestones, reflecting institutional uptake at leading academic centers. (GlobeNewswire / The Manila Times, Jan 2026.)

UCSF Benioff Children’s Hospitals (entry 1)

UCSF Benioff Children’s Hospitals are cited by SeaStar as an adopter and reporter of clinical outcomes for SCD therapy during the company’s first full commercial year (FY2026). (GlobeNewswire / The Manila Times, Jan 2026.)

University of Michigan

University of Michigan is included among prominent pediatric medical centers adopting the SCD and contributing clinical experience referenced in SeaStar’s FY2026 milestone communications. (GlobeNewswire / The Manila Times, Jan 2026.)

Children’s Hospital of Atlanta – Arthur M. Blank

Children’s Hospital of Atlanta – Arthur M. Blank is listed as a participating site in SeaStar’s SAVE Registry for pediatric patients receiving QUELIMMUNE, per coverage of 90‑day survival data. (QuiverQuant, Mar 2026.)

Children’s Hospital of Atlanta – Scottish Rite

Children’s Hospital of Atlanta – Scottish Rite appears on the SAVE Registry participant list reporting clinical experience with SeaStar’s pediatric therapy. (QuiverQuant, Mar 2026.)

Children’s Hospital of Philadelphia

Children’s Hospital of Philadelphia is named among top pediatric centers participating in the SAVE Registry and contributing to reported outcomes for QUELIMMUNE. (QuiverQuant, Mar 2026.)

Children’s Medical Center Dallas

Children’s Medical Center Dallas is documented as a SAVE Registry participant, indicating clinical use and data contribution for SeaStar’s pediatric SCD. (QuiverQuant, Mar 2026.)

Children’s of Alabama

Children’s of Alabama is listed on the registry of institutions collecting outcomes on QUELIMMUNE and is part of SeaStar’s institutional footprint for FY2026 reporting. (QuiverQuant, Mar 2026.)

Cincinnati Children’s Medical Center

Cincinnati Children’s Medical Center is separately listed among registry participants reporting on QUELIMMUNE outcomes in the company’s SAVE Registry disclosures. (QuiverQuant, Mar 2026.)

Cleveland Clinic Children’s Hospital

Cleveland Clinic Children’s Hospital is included on SeaStar’s SAVE Registry participant list and is a clinical user noted in FY2026 coverage. (QuiverQuant, Mar 2026.)

Cook Children’s Hospital

Cook Children’s Hospital appears among registry participants providing pediatric clinical experience with QUELIMMUNE. (QuiverQuant, Mar 2026.)

CS Mott Children’s Hospital

CS Mott Children’s Hospital is named as one of the SAVE Registry sites contributing data to SeaStar’s FY2026 pediatric outcomes reporting. (QuiverQuant, Mar 2026.)

Lucille Packard Children’s Hospital Stanford

Lucille Packard Children’s Hospital Stanford is included among the leading pediatric centers participating in SeaStar’s registry and publishing clinical experience with the SCD. (QuiverQuant, Mar 2026.)

Lurie Children’s Hospital of Chicago

Lurie Children’s Hospital of Chicago is listed as a SAVE Registry participant and institutional user in SeaStar’s FY2026 disclosures. (QuiverQuant, Mar 2026.)

Texas Children’s Hospital

Texas Children’s Hospital appears on SeaStar’s registry participant roster and is cited in reporting on 90‑day survival data for pediatric SCD therapy. (QuiverQuant, Mar 2026.)

UCSF Benioff Children’s (entry 2)

UCSF Benioff Children’s is also specifically enumerated in QuiverQuant’s SAVE Registry coverage, reinforcing its role as a reporting clinical site for QUELIMMUNE outcomes. (QuiverQuant, Mar 2026.)

What the relationship map implies about SeaStar’s operating model

SeaStar’s customer signals and corporate disclosures point to a hospital-centered, hardware-led commercial model with explicit regulatory and reimbursement dependencies:

  • Commercial posture: SeaStar is an active seller of a medical device (SCD) and transitioned from a distributor-led strategy to building internal commercial capacity after terminating the prior Distribution Agreement; the company shipped its first commercial units in July 2024 and recognized early revenues in 2024. This is a company-level operating fact tied to revenue and go-to-market design (FY2024–FY2026 filings).

  • Contracting and term structure: Evidence supports a mix of contracting types—historical exclusive licensing/distribution arrangements and longer-term supply provisions—combined with short-term, order‑by‑order product sales as the company builds its direct sales pipeline. This creates both revenue flexibility and dependency on achieving recurring hospital buys.

  • Concentration and criticality: Early revenues are concentrated (five active commercial sites reported) and product adoption is critical to scale; the business is dependent on a limited number of institutions and on favorable CMS/private-payer coverage decisions for expansion.

  • Geographic focus: SeaStar’s commercialization is U.S.-centric; all quoted sales and FDA HDE approval relate to U.S. pediatric markets, while the company signals interest in international markets later—this concentrates reimbursement and regulatory risk in U.S. policy and CMS engagement.

  • Maturity and ramp: Relationships are early to ramping—commercial shipments began in 2024, multiple high-profile academic centers are participating in registries, and adult indications remain in pivotal trials. This positions SeaStar at a commercialization inflection but still dependent on clinical publications, broader hospital penetration, and reimbursement clarity.

  • Financial footprint: Spend signals tied to commercial relationships are modest to mid-range—settlement and refund flows in 2024 were in the $100k–$1M band, while available liquidity lines referenced in filings suggest access to larger capital pools if needed. These are company-level financial signals from FY2024–FY2025 filings.

For institutional due diligence and model stress-testing, investors should evaluate uptake velocity at the named registry sites, cadence of peer-reviewed clinical outcome publications, and the timeline for adult pivotal results and payer engagements. For a systematic view of SeaStar’s customer exposures and to monitor updates, visit NullExposure: https://nullexposure.com/

Bottom line and investor actions

SeaStar has converted clinical credibility into early commercial adoption at leading pediatric hospitals and is building direct sales capability after a terminated distributor relationship; the company’s value hinges on converting registry evidence into standard-of-care adoption and on securing durable reimbursement for broader hospital use. Investors should track registry publications, unit shipment growth beyond the initial five commercial sites, and the adult SCD pivotal timeline.

If you evaluate institutional counterparties or need a tailored exposure report, start here: https://nullexposure.com/ — and revisit as SeaStar publishes registry outcomes and commercial metrics that will materially affect adoption and valuation.